Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Nature Structural & Molecular Biology|October 19, 2004
Shape-selective RNA recognition by cysteinyl-tRNA synthetaseScott Hauenstein, Chun-Mei Zhang, Ya-Ming Hou, et al.Journal of Molecular Biology|February 17, 2007
Kinetic quality control of anticodon recognition by a eukaryotic aminoacyl-tRNA synthetaseCuiping Liu, Howard Gamper, Svetlana Shtivelband, et al.The American Journal of Gastroenterology|February 20, 2013
Antibody response to infliximab and its impact on pharmacokinetics can be transientNiels Vande Casteele, Ann Gils, Sharat Singh, et al.Plos One|March 17, 2022
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemiaDawne N Shelton, Prasanthi Bhagavatula, Nathan Sepulveda, et al.Journal of Immunological Methods|June 14, 2012
Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serumShui-Long Wang, Linda Ohrmund, Scott Hauenstein, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 4, 2014
Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapyFilip Baert, David Drobne, Ann Gils, et al.Gut|April 12, 2015
Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trialFilip Baert, Venkateswarlu Kondragunta, Steven Lockton, et al.Journal of Pharmaceutical and Biomedical Analysis|March 5, 2013
Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assayShui-Long Wang, Scott Hauenstein, Linda Ohrmund, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2014
Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remissionKonstantinos Papamichael, Niels Vande Casteele, Ann Gils, et al.Inflammatory Bowel Diseases|January 9, 2015
Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBDNaamah L Zitomersky, Benjamin J Atkinson, Kerri Fournier, et al.Pageof 2